BJU International最新文献

Like most journals, BJUI relies on the hard work and dedication of its peer reviewers and we are grateful to them all. Each month the Editorial Team nominates peer reviewers whose reviews have stood out for their quality and timeliness and those selected as the best are highlighted on this page in recognition of their exceptional work.

As an author, I enjoyed the remarkable editorial standards as well as the exceptional international exposure provided by BJUI, while publishing the most relevant aspects of my clinical research focusing on the minimally invasive therapeutic approaches in non-muscle invasive bladder cancer and benign prostatic obstruction, areas of expertise that I felt most passionate about.

Most importantly, while constantly being involved as speaker, moderator and abstract reviewer for the most important urological international events, I strongly appreciated the BJUI impressive capacity of promoting the most recent diagnostic and treatment technological advances while maintain state-of-the-art scientific reliability based on rigorous selection criteria and impeccable data accuracy.

From all these perspectives, I am deeply honoured by my nomination as BJUI Reviewer of the Month, which I consider as one of the most relevant achievements of my academic career and a memorable recognition of my dedication to your prestigious journal.

He completed further training as a clinical fellow in Minimally Invasive Surgery/Endourology at the Glickman Urological and Kidney Institute at the Cleveland Clinic Foundation in Cleveland, OH. After completing training in the summer of 2009, he returned home to Vermont and joined the faculty at UVM. He remains a busy clinician and has developed a particular interest in health policy and advocacy. He participated in the 2017 AUA Leadership Program and currently serves on the Board of Directors for the AACU, the Board of Governors for the Vermont Medical Society, as a Member of the AUA State Advocacy Committee and is the current Secretary for the New England Section of the AUA.

Dr. Mousa's research focuses on testicular and prostate cancer, with an emphasis on oncologic outcomes, treatment-related morbidity, survivorship, and population-based analyses of cancer care delivery. He has authored multiple peer-reviewed publications in leading journals, including BJUI, European Urology Oncology, Cancer, and JNCI.

He is actively involved in medical education and academic service and is committed to providing rigorous, fair, and constructive peer review to support the dissemination of high-quality urologic oncology research.

Objective: To compare the long-term outcomes of the two main types of malleable erectile implants after phalloplasty in transgender men: models originally designed for cisgender men (conventional models) or the more recently developed Zephyr Surgical Implants (Geneva, Switzerland) female-to-male 100 implant (ZSI FtM 100) specifically for phalloplasty.

Patients and methods: A retrospective cohort study was conducted in patients who had undergone phalloplasty followed by insertion of a malleable implant between 2012 and 2015.

Results: A total of 32 patients were included who underwent a total of 48 implantation procedures, 22 of which were using the ZSI FtM 100, 24 the Coloplast Genesis, and two the Boston Scientific Spectra. There was no significant difference in postoperative complications, including infection or haemorrhage, between the two groups. For rates of late complications occurring after ≥1 month (infection, breakage, malposition, erosion, and chronic pain), conventional models had significantly more occurrences overall (P = 0.05) and these events were more likely to occur sooner (hazard ratio 2.3, 95% confidence interval 1.2-4.8; P = 0.02). At 24 months postoperatively, 74% of the ZSI FtM 100 devices remained complication free compared to 12% of the conventional models (P < 0.001). However, when separately comparing rates of specific complications, only a single significant difference was found, with the ZSI FtM 100 implants showing more incidents of breakage (P = 0.04).

Conclusion: The ZSI FtM 100 appears more prone to mechanical failure than conventional models but is associated with a lower overall incidence of complications. It also demonstrates a better lifespan in phalloplasty, with a longer complication-free survival. These findings must be interpreted with caution given the retrospective design and small sample size of this study.